 This systematic review found that many studies evaluating the effectiveness, tolerability and safety of anti-calcitonine gene-related peptid pathway monoclonal antibodies for the preventive treatment of migraine had inconsistent definitions of primary endpoints, outcomes, lack of longitudinal monitoring, and poor quality. Therefore, standardization of terminology, definitions and practical procedures for real-world evidence studies of preventive treatments for migraine are recommended. This article was authored by Nicholas Vandenbusch, Carolina Pisarek, and Coompe Melaire.